{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:30:58Z","timestamp":1790965858465,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13555-021-00596-8","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:02:22Z","timestamp":1630530142000},"page":"1763-1776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors"],"prefix":"10.1007","volume":"11","author":[{"given":"Anjaneya","family":"Chimalakonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Catlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab G.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Throup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"issue":"4","key":"596_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"M Nogueira","year":"2020","unstructured":"Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341\u201351.","journal-title":"Drugs"},{"issue":"1","key":"596_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","volume":"10","author":"A Kvist-Hansen","year":"2020","unstructured":"Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb). 2020;10(1):29\u201342.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"596_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/14728214.2020.1745773","volume":"25","author":"EA Balogh","year":"2020","unstructured":"Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020;25(2):89\u2013100.","journal-title":"Expert Opin Emerg Drugs"},{"key":"596_CR4","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"issue":"2","key":"596_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175\u201387.","journal-title":"Ann Rheum Dis"},{"key":"596_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","volume":"9","author":"MP Sch\u00f6n","year":"2018","unstructured":"Sch\u00f6n MP, Erpenbeck L. The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323.","journal-title":"Front Immunol"},{"issue":"8","key":"596_CR7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","volume":"204","author":"M Gadina","year":"2020","unstructured":"Gadina M, Chisolm DA, Philips RL, et\u00a0al. Translating JAKs to jakinibs. J Immunol. 2020;204(8):2011\u201320.","journal-title":"J Immunol"},{"issue":"4","key":"596_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343.","journal-title":"Nat Rev Rheumatol"},{"key":"596_CR9","unstructured":"Xeljanz (tofacitinib) [package insert]. New York: Pfizer Inc.; 2020. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed 23 Aug 2021."},{"key":"596_CR10","unstructured":"Olumiant (baricitinib) [package insert]. Indianapolis, IN: Lilly USA, LLC; 2020. Available at: http:\/\/pi.lilly.com\/us\/olumiant-uspi.pdf. Accessed 23 Aug 2021."},{"key":"596_CR11","unstructured":"Rinvoq (upadacitinib) [package insert]. Sligo, Ireland: AbbVie Ireland NL B.V.; 2020. Available at: https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 23 Aug 2021."},{"issue":"6","key":"596_CR12","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, et\u00a0al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554-73.e12.","journal-title":"Gastroenterology"},{"issue":"502","key":"596_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, et\u00a0al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):1\u201316.","journal-title":"Sci Transl Med"},{"issue":"20","key":"596_CR14","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, et\u00a0al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973\u201395.","journal-title":"J Med Chem"},{"issue":"14","key":"596_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Thaci D, et\u00a0al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313\u201321.","journal-title":"N Engl J Med"},{"key":"596_CR16","doi-asserted-by":"crossref","unstructured":"Armstrong A, Gooderham M, Warren R, et\u00a0al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the POETYK PSO-1 study [abstract]. In: Presented at: the annual meeting of the American Academy of Dermatology; April 23\u201325, 2021","DOI":"10.1136\/annrheumdis-2021-eular.1002"},{"key":"596_CR17","unstructured":"Girgis IG, Chimalakonda A, Kundu S, et\u00a0al. Exposure-efficacy response modelling of BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in a phase 2 study in psoriasis [poster P066]. Presented at: the triennial meeting of the Skin Inflammation & Psoriasis International Network; April 25\u201327, 2019; Paris, France"},{"issue":"8","key":"596_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40262-019-00739-3","volume":"58","author":"B Kl\u00fcnder","year":"2019","unstructured":"Kl\u00fcnder B, Mittapalli RK, Mohamed MF, et\u00a0al. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I\u2013III clinical trials. Clin Pharmacokinet. 2019;58(8):1045\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"596_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5414\/CP203516","volume":"57","author":"R Xie","year":"2019","unstructured":"Xie R, Deng C, Wang Q, et\u00a0al. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis. Int J Clin Pharmacol Ther. 2019;57(9):464\u201373.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"596_CR20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/psp4.12251","volume":"6","author":"X Zhang","year":"2017","unstructured":"Zhang X, Chua L, Ernest C 2nd, et\u00a0al. Dose\/exposure-response modeling to support dosing recommendation for phase III development of baricitinib in patients with rheumatoid arthritis. CPT Pharmacomet Syst Pharmacol. 2017;6(12):804\u201313.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"596_CR21","doi-asserted-by":"publisher","first-page":"e00537","DOI":"10.1002\/prp2.537","volume":"7","author":"ME Dowty","year":"2019","unstructured":"Dowty ME, Lin TH, Jesson MI, et\u00a0al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537.","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"596_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, et\u00a0al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"596_CR23","doi-asserted-by":"crossref","unstructured":"Gordon K, Papp K, Gooderham M, et\u00a0al. BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: evaluation of changes in laboratory parameters in response to treatment in a Phase 2 trial in psoriasis [poster]. Presented at: the American Academy of Dermatology Annual Meeting; March 20\u201324, 2020; Denver, CO","DOI":"10.25251\/skin.4.supp.28"},{"key":"596_CR24","unstructured":"Mease PJ, Deodhar A, van der Heijde D, et\u00a0al. Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial [poster L03]. Presented at: the annual scientific meeting of the American College of Rheumatology; November 5\u20139, 2020; virtual meeting"},{"issue":"1","key":"596_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, et\u00a0al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"596_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jcph.1513","volume":"60","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Beck D, Camp HS, Othman AA. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol. 2020;60(2):188\u201397.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"596_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1124\/jpet.113.209304","volume":"348","author":"ME Dowty","year":"2014","unstructured":"Dowty ME, Jesson MI, Ghosh S, et\u00a0al. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J Pharmacol Exp Ther. 2014;348(1):165\u201373.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00596-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T18:02:17Z","timestamp":1633024937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00596-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00596-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}